Btk inhibition: the importance of being selective.
作者信息
Flaumenhaft Robert
机构信息
Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA.
出版信息
Blood Adv. 2024 Nov 12;8(21):5579-5580. doi: 10.1182/bloodadvances.2024014009.
Abstract
摘要
相似文献
1
Btk inhibition: the importance of being selective.布鲁顿酪氨酸激酶（Btk）抑制：选择性的重要性
Blood Adv. 2024 Nov 12;8(21):5579-5580. doi: 10.1182/bloodadvances.2024014009.
2
Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice.PRN1008/PRN473 通过选择性抑制 BTK 阻断人 CLEC-2，且 PRN473 可减少小鼠静脉血栓形成。
Blood Adv. 2024 Nov 12;8(21):5557-5570. doi: 10.1182/bloodadvances.2024012713.
3
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.联合抑制 Tec 激酶 BTK 和 ITK 有益于改善小鼠硬皮病慢性移植物抗宿主病。
Bone Marrow Transplant. 2023 Aug;58(8):924-935. doi: 10.1038/s41409-023-02001-8. Epub 2023 May 9.
4
Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.选择性抑制 BTK 可预防小鼠狼疮和抗体介导的肾小球肾炎。
J Immunol. 2013 Nov 1;191(9):4540-50. doi: 10.4049/jimmunol.1301553. Epub 2013 Sep 25.
5
Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.布鲁顿酪氨酸激酶抑制作用及其作为天疱疮新兴治疗方法的作用
Front Med (Lausanne). 2021 Aug 10;8:708071. doi: 10.3389/fmed.2021.708071. eCollection 2021.
6
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.通过高度选择性抑制布鲁顿酪氨酸激酶对免疫复合物介导的肾小球肾炎进行治疗性阻断
Sci Rep. 2016 May 19;6:26164. doi: 10.1038/srep26164.
7
Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective Inhibition to the BTK/HCK Dual Inhibition - Delving into the Inhibitory Activity of KIN-8194 against BTK, and HCK in the Treatment of Mutated Waldenström Macroglobulinemia: A Computational Approach.揭示 Arg 和 Lys 在从 BTK 选择性抑制到 BTK/HCK 双重抑制转变中的作用 - 探讨 KIN-8194 对 BTK 和 HCK 的抑制活性在治疗突变型 Waldenström 巨球蛋白血症中的作用：一种计算方法。
Anticancer Agents Med Chem. 2024;24(11):813-825. doi: 10.2174/1871520623666230208102609.
8
Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis.发现口服活性1,4,5,6,8-五氮杂苊烯作为新型、选择性且强效的共价BTK抑制剂用于治疗类风湿性关节炎。
Eur J Med Chem. 2023 Jan 15;246:114940. doi: 10.1016/j.ejmech.2022.114940. Epub 2022 Nov 25.
9
Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.新型高选择性抑制剂 CHMFL-BTK-11 不可逆抑制 BTK 激酶可抑制类风湿关节炎模型中的炎症反应。
Sci Rep. 2017 Mar 28;7(1):466. doi: 10.1038/s41598-017-00482-4.
10
The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity.Btk 抑制剂 AB-95-LH34 能够有效抑制动脉粥样硬化斑块诱导的血栓形成和血小板促凝活性。
J Thromb Haemost. 2022 Dec;20(12):2939-2952. doi: 10.1111/jth.15899. Epub 2022 Oct 17.
本文引用的文献
1
Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice.PRN1008/PRN473 通过选择性抑制 BTK 阻断人 CLEC-2，且 PRN473 可减少小鼠静脉血栓形成。
Blood Adv. 2024 Nov 12;8(21):5557-5570. doi: 10.1182/bloodadvances.2024012713.
2
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.利扎鲁单抗，一种口服 BTK 抑制剂，治疗免疫性血小板减少症。
N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297.
3
Functional significance of the platelet immune receptors GPVI and CLEC-2.血小板免疫受体 GPVI 和 CLEC-2 的功能意义。
J Clin Invest. 2019 Jan 2;129(1):12-23. doi: 10.1172/JCI122955.
4
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.接受阿卡拉布替尼治疗的患者不存在接受依鲁替尼治疗的非霍奇金淋巴瘤（NHL）患者中出现的严重血小板功能障碍。
Blood Adv. 2017 Dec 12;1(26):2610-2623. doi: 10.1182/bloodadvances.2017011999.
5
Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis.CLEC-2 缺乏的小鼠对深静脉血栓形成具有抵抗力。
Blood. 2017 Apr 6;129(14):2013-2020. doi: 10.1182/blood-2016-09-742999. Epub 2017 Jan 19.
6
Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets.炎症通过血小板上的CLEC-2在沙门氏菌感染后引发血栓形成。
J Clin Invest. 2015 Dec;125(12):4429-46. doi: 10.1172/JCI79070. Epub 2015 Nov 16.
7
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.伊布替尼治疗复发慢性淋巴细胞白血病的 BTK 靶点。
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
8
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.伊布替尼治疗复发或难治性套细胞淋巴瘤中的 BTK。
N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
9
Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.免疫缺陷XID小鼠中布鲁顿酪氨酸激酶独特区域的突变
Science. 1993 Jul 16;261(5119):358-61. doi: 10.1126/science.8332901.
10
Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes.X连锁无丙种球蛋白血症与X连锁免疫缺陷基因的共定位。
Science. 1993 Jul 16;261(5119):355-8. doi: 10.1126/science.8332900.
Zotero 插件